Preparation and study of the characteristics of dithranol: Polyvinylpyrrolidone coevaporates

International Journal of Pharmaceutics

Volumn 168, Issue 1, 1998, Pages 109-118

  Delneuville, I ^a   Dechesne, J P ^a   Delattre, L ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Coevaporate; Colloidal dispersion; Dithranol; Polyvinylpyrrolidone

Indexed keywords

DANTRON; DITHRANOL; DRUG VEHICLE; POVIDONE;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG FORMULATION; DRUG SCREENING; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROPHILICITY; PARTICLE SIZE; PRIORITY JOURNAL; PSORIASIS; TOPICAL TREATMENT; X RAY DIFFRACTION;

EID: 0032496614     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(98)00089-1     Document Type: Article

References (32)

1. Ashton R.E., Andre P., Lowe N.J., Whitefield M. Anthralin: historical and current perspectives. J. Am. Acad. Dermatol. 9:1983;173-192.
2. Chiou W.L., Riegelman S. Pharmaceutical applications of solid dispersion systems. J. Pharm. Sci. 60:1971;1281-1302.
3. Corrigan O., Timoney R. The influence of polyvinylpyrrolidone on the dissolution properties of hydroflumethiazide. J. Pharm. Pharmacol. 27:1975;759-764.
4. Doherty C., York P. Evidence for solid- and liquid-state interactions in a furosemide-polyvinylpyrrolidone solid dispersion. J. Pharm. Sci. 76:1987;731-737.
5. Duchêne D. Les dispersions solides, stabilité et conservation. S.T.P. Pharm. Sci. 1:1985;1064-1074.
6. European Pharmacopoeia, 1997, 3rd ed., Council of Europe, Strasbourg, pp. 789-791.
7. Ford J.L. The current status of solid dispersions. Pharm. Acta Helv. 61:1986;69-88.
8. Gehring W., Ghyczy M., Gareiss J., Gloor M. Influence on skin penetration by dithranol formulated in phospholipid solutions and phospholipid liposomes. Eur. J. Pharm. Biopharm. 41:1995;140-142.
9. Hajratwala B.R., Ho D.S. Dissolution of hydrocortisone from polyvinylpyrrolidone dispersions. Aust. J. Pharm. Sci. 10:1981;70-73.
10. Holder A.J., Upadrashta S.M. A semiempirical computational investigation of the antipsoriatic drug anthralin. J. Pharm. Sci. 81:1992;1074-1078.
11. Kearney A., Gabriel D., Mehta S., Radebaugh G. Effect of polyvinylpyrrolidone on the crystallinity and dissolution rate of solid dispersions of the antiinflammatory CI-987. Int. J. Pharm. 104:1994;169-174.
12. Kneczke M., Rahm C., Landersjö L. In vitro release of anthralin from white petrolatum and o/w cream. Acta Pharm. Nord. 1:1989;249-258.
13. Kudsi S., De Bersaques J., Geerts M.L., Kint A., Remon J.P., De Muynck C. Water-miscible dithranol cream in the treatment of psoriasis. J. Dermatol. Treat. 1:1991;19-22.
14. Lindahl, A., 1992. Embedding of dithranol in lipid crystals. Acta Derm. Venereol. (Stockh.) Suppl. 172, 13-16.
15. Morita M., Hirota S. Effect of crystallinity on the percutaneous absorption of corticosteroid. II. Chemical activity and biological activity. Chem. Pharm. Bull. 33:1985;2091-2097.
16. Oth M.P., Moës A.J. Enhanced in vitro release of indomethacin from non-aqueous suspensions using indomethacin-polyvinylpyrrolidone coprecipitate. Int. J. Pharm. 24:1985;275-286.
17. Rodriguez-Hornedo, 1990. Crystallisation and the properties of crystals. In: Swarbrick, J., Boylan, J.C. (Eds.), Encyclopedia of Pharmaceutical Technology, Marcel Dekker, New York, pp. 399-434.
18. Ros J.J., Van der Meer Y.G. Preparation, analysis and stability of oil-in-water creams containing dithranol. Eur. J. Hosp. Pharm. 1:1991;77-84.
19. Ros J.J., Van der Meer Y.G., De Hoop D., De Kort W.J., Van Andel P. In vitro and in vivo comparison of creams containing dithranol 0.5%. Pharm. Weekbl. [Sci.]. 13:1991;210-214.
20. Sekikawa H., Nakano M., Arita T. Inhibitory effect of polyvinylpyrrolidone on the crystallization of drug. Chem. Pharm. Bull. 26:1978;118-126.
21. Sekikawa H., Nakano M., Arita T. Dissolution mechanisms of drug-polyvinylpyrrolidone coprecipitates in aqueous solution. Chem. Pharm. Bull. 27:1979;1223-1230.
22. Seville R.H., Walker G.B., Whitefield M. Dithranol cream. Br. J. Dermatol. 100:1979;475.
23. Shefter E., Cheng K. Drug-polyvinylpyrrolidone (PVP) dispersions. A differential scanning calorimetric study. Int. J. Pharm. 6:1980;179-182.
24. Simonelli A.P., Mehta S.C., Higuchi W.I. Dissolution rates of high energy polyvinylpyrrolidone-sulfathiazole coprecipitates. J. Pharm. Sci. 58:1969;538-549.
25. Simonelli A.P., Mehta S.C., Higuchi W.I. Inhibition of sulfathiazole crystal growth by PVP. J. Pharm. Sci. 59:1970;633-637.
26. Simonelli A.P., Mehta S.C., Higuchi W.I. Dissolution rates of high energy sulfathiazole-povidone coprecipitates II: characterization of form of drug controlling its dissolution rate via solubility studies. J. Pharm. Sci. 65:1976;355-361.
27. Tachibana T., Nakamura A. A method for preparing an aqueous colloidal dispersion of organic materials by using water-soluble polymers: dispersion of β-carotene by polyvinylpyrrolidone. Kolloid-Z Polym. 203:1965;130-133.
28. Tantishaiyakul V., Kaewnopparat N., Ingkatawornwong S. Properties of solid dispersions of piroxicam in polyvinylpyrrolidone K-30. Int. J. Pharm. 143:1996;59-66.
29. Thakkar A.L., Hirsch C.A., Page J.G. Solid dispersion approach for overcoming bioavailability problems due to polymorphism of nabilone, a cannabinoid derivative. J. Pharm. Pharmacol. 29:1977;783-784.
30. Van Hal, D.A., Bouwstra, J.A., de Vringer, T., Junginger, H.E., 1994. Encapsulation and stability of dithranol (anthralin) in nonionic surfactant vesicles. Ph.D. Thesis, Leiden/Amsterdam Center for Drug Research, Leiden University, The Netherlands, pp. 59-78.
31. Whitefield M. Pharmaceutical formulations of anthralin. Br. J. Dermatol. 105(S20):1981;28-32.
32. Wilson P.D., Ive F.A. Dithrocream in psoriasis. Br. J. Dermatol. 102:1980;105.